From an expert perspective, the development of GLP-1RAs has marked a pivotal advancement by targeting key pathophysiological mechanisms such as hepatic lipid metabolism, inflammation, and fibrosis
The Phase 2 trial results Published in the New England Journal of Medicine, the Phase 2 trial showed that participants receiving the highest dose of retatrutide (12mg weekly) achieved a mean weight reduction of 24.2% at 48 weeks
Vrkonyi T, Del Prato S, Pavo I, Nicolay C, Wiese RJ, Kahn SE
This gives you time to obtain any additional documentation or approvals required
Looking ahead, we are excited to announce the upcoming launch of our Cardiometabolic Program in Q3 2024
Prepare Questions: Jot down any questions or concerns you may have about the treatment process, potential side effects, or lifestyle adjustments